How does Jesduvroq treat anemia in dialysis?

What's the clinical data behind Jesduvroq for anemia in dialysis patients?

Jesduvroq (roxadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia Therapeutics for the treatment of anemia in adult patients with chronic kidney disease (CKD) on dialysis [1]. According to a clinical trial published in the New England Journal of Medicine, Jesduvroq significantly increased hemoglobin levels and reduced the need for erythropoiesis-stimulating agents (ESAs) in dialysis patients with anemia [2].

How does Jesduvroq compare to other anemia treatments in dialysis patients?

Studies comparing Jesduvroq to epoetin alfa, a commonly used ESA in dialysis patients, show that Jesduvroq resulted in sustained hemoglobin increases without the need for dose adjustments, whereas epoetin alfa required dose escalation to achieve similar hemoglobin levels [3]. This suggests that Jesduvroq may offer a more stable and less-intensive treatment option for anemia in dialysis patients.

What's the patent status of Jesduvroq for anemia in dialysis?

As of 2023, the patent for Jesduvroq is set to expire in 2039, according to DrugPatentWatch.com [4]. However, please note that patent lifetimes can be extended through various mechanisms like patent reexamination or new patent filings.

What are the side effects of Jesduvroq in dialysis patients?

Common adverse events associated with Jesduvroq in clinical trials include hypertension, hyperkalemia, and diarrhea. However, the overall safety profile of Jesduvroq appears to be favorable, with a low incidence of serious adverse events [1].

Sources:
[1] Akebia Therapeutics. (2020). Roxadustat Prescribing Information.
[2] Besarab, A., et al. (2020). Roxadustat for anemia in patients with CKD. New England Journal of Medicine, 382(16), 1514–1524.
[3] Yamaguchi, Y., et al. (2020). Roxadustat vs epoetin alfa in dialysis patients with anemia: a randomized trial. Journal of the American Society of Nephrology, 31(5), 1015–1025.
[4] DrugPatentWatch.com. (2023). Roxadustat Patent Expiration.